Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema.
A 59-year-old male patient with tamoxifen induced macular edema in both eyes was treated with intravitreous sodium pegaptanib. Follow-up clinical examination, OCT, and FA demonstrated reduced edema and leakage with improvement in visual acuity.
Bourla
Dan H
DH
Jules Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA 90095, USA. bourla@jsei.ucla.edu
Gonzales
Christine R
CR
Mango
Charles W
CW
Moral
Joel N
JN
Wirthlin
Robert S
RS
Schwartz
Steven D
SD
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D018931:Antineoplastic Agents, Hormonal; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; D013629:Tamoxifen; C495058:pegaptanib